Pharmaceutical

Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC

The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.

Aug 12, 2023 - 20:00
Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC
The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.
Read the original article

Tags:

Previous Article

STAT+: Where are patients getting their prescriptions for GLP-1 drugs like Wegov...

Next Article

TriSalus merges with MedTech Acquisition to bolster cash reserves

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Health data breaches hit an all-time high in 2023

STAT+: Health data breaches hit an all-time high in 2023

Dec 25, 2023

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria ...

Aug 7, 2024

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likelihood of Approval

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likel...

Nov 2, 2023